We are live on
!
Find out more
SGH
Sivik Global Healthcare Portfolio holdings
AUM
$132M
1-Year Est. Return
24.1%
This Fund
S&P 500
This Quarter
Est. Return
+6.7%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$344M
AUM Growth
-$23.9M
(-6.5%)
Cap. Flow
-$31.8M
Cap. Flow
% of AUM
-9.24%
Top 10 Holdings %
Top 10 Hldgs %
51.87%
Holding
64
New
18
Increased
3
Reduced
20
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$6.52M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$5.85M |
| 3 |
Johnson & Johnson
JNJ
|
+$4.28M |
| 4 |
AbbVie
ABBV
|
+$4.07M |
| 5 |
Zimmer Biomet
ZBH
|
+$3.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tenet Healthcare
THC
|
+$8.87M |
| 2 |
NVO
Novo Nordisk
NVO
|
+$6.9M |
| 3 |
Waters Corp
WAT
|
+$6.28M |
| 4 |
Gilead Sciences
GILD
|
+$5.54M |
| 5 |
Universal Health Services
UHS
|
+$4.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 48.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Zimmer Biomet
ZBH
$18.7B
| $3.94M | 1.15% |
+40,000
| New | +$3.96M |
|
27
West Pharmaceutical
WST
$24.8B
| $3.94M | 1.14% |
15,000
| – | – |
|
28
Quest Diagnostics
DGX
$26.2B
| $3.81M | 1.11% |
20,000
-5,000
| -20% | -$887K |
|
29
Repligen
RGEN
$9.35B
| $3.68M | 1.07% |
27,500
-2,500
| -8% | -$304K |
|
30
Bio-Rad Laboratories Class A
BIO
$9.68B
| $3.08M | 0.9% |
11,000
-7,000
| -39% | -$1.9M |
|
31
Labcorp
LH
$26.2B
| $2.87M | 0.84% |
+10,000
| New | +$2.68M |
|
|
SEM
32
DELISTED
Select Medical
SEM
| $2.25M | 0.65% |
175,000
-125,000
| -42% | -$1.67M |
|
33
Stevanato
STVN
$5.8B
| $2.19M | 0.64% |
+85,000
| New | +$2.1M |
|
34
Bruker
BRKR
$9.03B
| $1.95M | 0.57% |
+60,000
| New | +$2.14M |
|
35
GE HealthCare
GEHC
$32.6B
| $1.88M | 0.55% |
+25,000
| New | +$1.86M |
|
36
Align Technology
ALGN
$12.4B
| – | – |
-15,000
| Closed | -$2.84M |
|
37
Alnylam Pharmaceuticals
ALNY
$30B
| – | – |
-6,500
| Closed | -$2.12M |
|
38
argenx
ARGX
$54.8B
| – | – |
-2,500
| Closed | -$1.38M |
|
39
Avantor
AVTR
$9.42B
| – | – |
-225,000
| Closed | -$3.03M |
|
40
Baxter International
BAX
$13.9B
| – | – |
-75,000
| Closed | -$2.27M |
|
41
Cooper Companies
COO
$15B
| – | – |
-30,000
| Closed | -$2.13M |
|
|
42
Gilead Sciences
GILD
$168B
| – | – |
-50,000
| Closed | -$5.54M |
|
43
Inspire Medical Systems
INSP
$1.68B
| – | – |
-10,000
| Closed | -$1.3M |
|
44
Madrigal Pharmaceuticals
MDGL
$12.4B
| – | – |
-5,000
| Closed | -$1.51M |
|
|
NVO
45
Novo Nordisk
NVO
$203B
| – | – |
-100,000
| Closed | -$6.9M |
|
46
Revvity
RVTY
$13.2B
| – | – |
-45,000
| Closed | -$4.35M |
|
|
47
Waters Corp
WAT
$40.9B
| – | – |
-18,000
| Closed | -$6.28M |
|
Similar funds
AFP
PCGDR
ACM
9C
STFP
ADEF
AC
CIP
Sivik Global Healthcare's Q3 2025 Portfolio in Review
As of Q3 2025, Sivik Global Healthcare held 64 positions worth $344M, down 6.5% from $368M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Sivik Global Healthcare withdrew a net $31.8M in Q3 2025, closing 20 positions and reducing 20 holdings. Its most notable exit was Novo Nordisk, an estimated $6.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 55% a quarter earlier.
Against the trend, Sivik Global Healthcare opened a new position in Thermo Fisher Scientific worth $6.79M.
- Sivik Global Healthcare's largest Q3 2025 buy was Thermo Fisher Scientific: 14,000 shares worth $6.79M.
- Sivik Global Healthcare added most to Surgery Partners in Q3 2025, an estimated $2.12M increase.
- Sivik Global Healthcare's biggest Q3 2025 reduction was Tenet Healthcare, cutting an estimated $8.87M.
- Sivik Global Healthcare fully exited Novo Nordisk in Q3 2025, selling an estimated $6.9M.
- Sivik Global Healthcare's ten largest holdings make up 52% of its $344M portfolio in Q3 2025.
- Sivik Global Healthcare opened 18 new positions and closed 20 in Q3 2025.
- Sivik Global Healthcare's portfolio value fell 6.5% quarter-over-quarter to $344M.
Based on Sivik Global Healthcare's 13F filing for Q3 2025, filed 23 Oct 2025.